EUVIMEDEUVIMED entdecken
Crossref

Genomic Profiling of Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System Suggests Novel Potential Therapeutic Targets

Claudio Agostinelli, Luca Morandi, Simona Righi, Luigi Cirillo, Marica Iommi, Caterina Tonon, Diego Mazzatenta, Matteo Zoli, Maura Rossi, Gianmarco Bagnato, Alessandro Broccoli, Raffaele Lodi und 4 weitere

Modern Pathology · 2023-12 · 36 (12) · 100323

DOI: 10.1016/j.modpat.2023.100323 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Modern Pathology, 2023-12. Verfasst von Claudio Agostinelli und 15 weiteren Autor:innen. Beteiligte Einrichtung: Haematopathology Unit, IRCCS Azienda Ospedaliero-Universitaria of Bologna, Bologna, Italy; Department of Medical and Surgical Sciences, University of…. Hauptthemen laut MEDLINE: Myeloid Differentiation Factor 88, Lymphoma, Large B-Cell, Diffuse. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 55 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Primary diffuse large B-cell lymphoma of the primary central nervous system (CNS-DLBCL) is an aggressive disease, with dismal prognosis despite the use of high-dose methotrexate-based polychemotherapy. Our study aimed to expand the biologic profiles of CNS-DLBCL and to correlate them with clinical/imaging findings to gain diagnostic insight and possibly identify new therapeutic targets. We selected 61 CNS-DLBCL whose formalin-fixed paraffin-embedded samples were available at first diagnosis. These were investigated by immunohistochemistry, cMYC rearrangements were explored by fluorescence in situ hybridization, and CNS-DLBCL mutated genes were evaluated by next-generation sequencing. CD10, BCL6, and IRF4 were observed in 16%, 83.6%, and 93% of cases, respectively. As typical of CNS lymphoma, 10 (16.4%) of 61 cases were classified as germinal center (GCB) type and 51 (83.6%) of 61 as non-germinal center (non-GCB) type according to the Hans algorithm. Double-expression status for BCL2 and cMYC was detected in 36 (59%) of 61 cases whereas 25 (41%) of 61 were non-DE. Rearrangement of the cMYC gene was detected in 2 cases, associated with BCL6 translocation only in 1 case MYD88, PIM1, CD79B, and TP53 were mutated in 54.5%, 53.5%, 30.2%, and 18.4% cases, respectively. Novel mutations not previously reported in CNS-DLBCL were found: AIP in 23.1%, PI3KCA in 15%, NOTCH1 in 11.4%, GNAS in 8.1%, CASP8 in 7.9%, EGFR in 6.4%, PTEN in 5.1, and KRAS in 2.6% of cases. Survival was significantly longer for patients with mutated MYD88 (8.7 months vs 1.7 months; log-rank test = 5.43; P = .020) and for patients with mutated CD79B (10.8 months vs 2.5 months; log-rank test = 4.64; P = .031). MYD88 and CD79B predicted a longer survival in patients affected by CNS-DLBCL. Notably, we identified novel mutations that enrich the mutational landscape of CNS-DLBCL, suggest a role of PTEN-PI3K-AKT and receptor tyrosine kinase-RAS-mitogen-activated protein kinase signaling in a subset of CNS-DLBCL, and provide new potential therapeutic targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloid Differentiation Factor 88Lymphoma, Large B-Cell, DiffuseHumansIn Situ Hybridization, FluorescencePhosphatidylinositol 3-KinasesCentral Nervous SystemPrognosisGenomics

Stichwörter der Autor:innen

B-cell lymphomaPTEN-PI3K-AKTRTK-RAS-MAPKcentral nervous system

Substanzen

Myeloid Differentiation Factor 88Phosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • Haematopathology Unit, IRCCS Azienda Ospedaliero-Universitaria of Bologna, Bologna, Italy; Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
  • Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy; IRCCS Istituto delle Scienze Neurologiche di Bologna, Functional and Molecular Neuroimaging Unit, Bologna, Italy.
  • Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
  • IRCCS Istituto delle Scienze Neurologiche di Bologna, Functional and Molecular Neuroimaging Unit, Bologna, Italy.
  • Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy.
  • IRCCS Istituto delle Scienze Neurologiche di Bologna, Center for the Diagnosis and Treatment of Hypothalamic-Pituitary Diseases, Pituitary Unit.

Zitieren

APA

Agostinelli, C., Morandi, L., Righi, S., Cirillo, L., Iommi, M., Tonon, C., Mazzatenta, D., Zoli, M., Rossi, M., Bagnato, G., Broccoli, A., Lodi, R., Zinzani, P. L., Sabattini, E., Giannini, C., & Asioli, S. (2023). Genomic Profiling of Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System Suggests Novel Potential Therapeutic Targets. Modern Pathology, 36(12), 100323. https://doi.org/10.1016/j.modpat.2023.100323

Vancouver

Agostinelli C, Morandi L, Righi S, Cirillo L, Iommi M, Tonon C, et al. Genomic Profiling of Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System Suggests Novel Potential Therapeutic Targets. Modern Pathology. 2023;36(12):100323. doi:10.1016/j.modpat.2023.100323

BibTeX
@article{Agostinelli2023,
  author = {Agostinelli, Claudio and Morandi, Luca and Righi, Simona and Cirillo, Luigi and Iommi, Marica and Tonon, Caterina and Mazzatenta, Diego and Zoli, Matteo and Rossi, Maura and Bagnato, Gianmarco and Broccoli, Alessandro and Lodi, Raffaele and Zinzani, Pier Luigi and Sabattini, Elena and Giannini, Caterina and Asioli, Sofia},
  title = {Genomic Profiling of Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System Suggests Novel Potential Therapeutic Targets},
  journal = {Modern Pathology},
  year = {2023},
  volume = {36},
  number = {12},
  pages = {100323},
  doi = {10.1016/j.modpat.2023.100323}
}
Kostenlos starten →